Luminal B-like (HER2 positive), also HER2+/HR+ breast cancer, is recommended for combined treatment of cytotoxicity, anti-HER2, and endocrine therapy (Goldhirsch et al., 2013; Cho, 2016). Here, ERBB2 is linked to breast carcinoma.